Aquestive Therapeutics (AQST) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 24.3% versus a loss of 23.2%. Over five years, XERS leads with a +409.5% price change compared with +23.0% for AQST. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $599.9 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | XERS |
|---|---|---|
| Share price | $4.78 | $10.48 |
| Market cap | $599.95M | $1.91B |
| 1-day change | +0.42% | +2.85% |
| YTD return | -26.32% | +29.81% |
| 1-year return | -23.23% | +24.27% |
| 5-year return | +23.00% | +409.50% |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $-0.66 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $7.55 | $11.33 |
| 52-week low | $2.93 | $5.25 |
| Distance from 52-week high | -36.69% | -7.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +95.19% | +22.71% |
| Average volume | 2.68M | 2.17M |
| Shares outstanding | 125.51M | 182.32M |
| Employees | 147 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Xeris Biopharma is about 3.2 times larger than Aquestive Therapeutics by market value ($1.91B vs $599.95M).
- XERS has outperformed AQST by 47.5 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
AQST vs XERS FAQ
Which is bigger, Aquestive Therapeutics or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $599.95M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or XERS?
XERS returned +24.27% over the past 12 months, compared with -23.23% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.